

## [Ifosfamide](#)

Essential medicine status

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.1. Cytotoxic medicines](#)

ATC codes: [L01AA06](#)

EMLc

Indication

Rhabdomyosarcoma primary site ICD11 code: [2C25.Z](#)

INN

Ifosfamide

Medicine type

Chemical agent

List type

Complementary

Formulations

**Parenteral > General injections > IV:** 500 mg in vial powder for injection ; 1 g in vial powder for injection ; 2 g in vial powder for injection

EML status history

First added in 2009 ([TRS 958](#))

Changed in 2015 ([TRS 994](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Tags

Cancer

Wikipedia

[Ifosfamide](#)

DrugBank

[Ifosfamide](#)

Summary of evidence and Expert Committee recommendations



In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for ifosfamide on the complementary list of the EML for use in treatment protocols for rhabdomyosarcoma was specifically endorsed. Additionally, ifosfamide was included on the complementary list of the EMLc for this indication. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for rhabdomyosarcoma is attached.